C3NIRA: Randomized phase II study of carboplatin-cabazitaxel-cetrelimab (anti-PD-1) induction followed by niraparib +/- cetrelimab maintenance in men with aggressive variant prostate cancers (AVPC).
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Ana Aparicio, Rebecca Slack Tidwell, Sreyashi Basu, Zhong He, Amado J. Zurita, Bilal Ahmed Siddiqui, Sumit Kumar Subudhi, Paul Gettys Corn, Craig A. Kovitz, Bagi Jana, Andrew Warren Hahn, Omar Alhalabi, Rahul Sheth, Jessica Deinert, Christopher Logothetis, Rama Soundararajan, Timothy C. Thompson, Padmanee Sharma, Patrick Glen Pilié
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Janssen Scientific Affairs
OpenAlex ID: W4410812152